On Demand 2017 Complications of PID (MOC)
Price: NOW 20% OFF! $20 members, $28 non-members
You can earn up to 1.75 AMA PRA Category 1 Credits™, and up to 1.75 MOC Part II Self-Assessment credits.
Many primary immunodeficiency disorders (PID) present with signs and symptoms of immune dysregulation. National data on non-infectious complications of PID is presented, along with a discussion of the evaluation of patients. Current information on the use of biologicals to treat specific immune deficiencies, as well as advances in this area, are highlighted.
- What We Know: Data From USIDNet on the Frequency of Non-infectious Complications of PID
- What We Need to Know: Evaluation of PID Patients With Immune Dysregulation
- Where Are We Going? Personalized Therapy for Monogeneic Immune Deficiency With Immune Dysregulation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 1.75 credits as meeting the requirements for MOC Part II Self-Assessment.
Medical professionals who treat patients with allergic and/or immunological conditions:
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
Upon completion of this session, participants should be able to:
- Describe the frequency of non-infectious complications of primary immunodeficiency.
- Recognize the manifestations of non-infectious complications of primary immunodeficiency and the appropriate evaluation of the patient.
- Be aware of the therapeutic options available for the treatment of monogeneic immunodeficiencies, including monoclonal antibodies.
- Richard L. Wasserman, MD, PhD, FACAAI
- Kathleen Sullivan, MD, PhD
- Troy Torgersen, MD, PhD
- Jennifer Leiding, MD
- 1.75 AMA PRA Category 1 Credit™
- 1.75 Attendance